The Latest

  • COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer
COUR Pharmaceuticals Logo

COUR Pharmaceuticals

  • Our Company
    • Leadership
    • Board of Directors
    • Advisors
    • Partners
    • Contact
  • Our Technology
    • Pipeline
  • Our Clinical Trials
    • CNP-106 Myasthenia Gravis
  • Publications & Media
    • Press Releases
    • Publications
  • Careers

News

Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis

… [Read more...] about Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis

Cour Pharma Presents Scientific Poster on Breakthrough Celiac Treatment at 16th Annual International Celiac Disease Symposium

Download Poster Here … [Read more...] about Cour Pharma Presents Scientific Poster on Breakthrough Celiac Treatment at 16th Annual International Celiac Disease Symposium

Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease

Proprietary Antigen-specific Nanoparticles and … [Read more...] about Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3

Footer

COUR Pharmaceuticals Logo
  • Our Company
  • Our Technology
  • Our Partners
  • Press
  • Careers

©

2025

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use

Back to Top